How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,774 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Epidemiology of venous thromboembolism. (PubMed)

Epidemiology of venous thromboembolism. Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is a fairly common disease, particularly in older age, and is associated with reduced survival, substantial health-care costs, and a high rate of recurrence. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis (...) and various risk factors. Major risk factors for incident VTE include hospitalization for surgery or acute illness, active cancer, neurological disease with leg paresis, nursing-home confinement, trauma or fracture, superficial vein thrombosis, and-in women-pregnancy and puerperium, oral contraception, and hormone therapy. Although independent risk factors for incident VTE and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence

Full Text available with Trip Pro

2015 Nature reviews. Cardiology

182. Statement on pregnancy and travel

of toxemia, hypertension, or diabetes with any pregnancy / Antécédents de toxémie, d’hypertension artérielle ou de diabète au cours d’une grossesse (passée ou présente) • Primigravida at 35 years of age and older, or 15 years of age and younger / Primigeste de 35 ans et plus ou de 15 ans et moins • History of thromboembolic disease / Antécédents de maladie thrombo- embolique • Pulmonary hypertension / Hypertension artérielle pulmonaire • Severe asthma or other chronic lung disease / Asthme grave ou autre (...) Statement on pregnancy and travel 1 CCDR Canada Communicable Disease Report RMTC Relevé des maladies transmissibles au Canada March 2010 • Volume 36 • ACS-2 March 2010 • Volume 36 • DCC-2 ISSN 1481-8531 Committee to Advise on Tropical Medicine and Travel* † STATEMENT ON PREGNANCY AND TRAVEL This correction note was published in the CCDR Volume 40-8 on April 17, 2014 The “Statement on Pregnancy and Travel” by the Committee to Advise on Tropical Medicine and Travel (CATMAT) † published in March

2010 CPG Infobase

183. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. (PubMed)

and 44 non-academic hospitals in the Netherlands. Women with non-severe hypertensive disorders of pregnancy between 34 and 37 weeks of gestation were randomly allocated to either induction of labour or caesarean section within 24 h (immediate delivery) or a strategy aimed at prolonging pregnancy until 37 weeks of gestation (expectant monitoring). The primary outcomes were a composite of adverse maternal outcomes (thromboembolic disease, pulmonary oedema, eclampsia, HELLP syndrome, placental abruption (...) Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. There is little evidence to guide the management of women with hypertensive disorders in late preterm pregnancy. We investigated the effect of immediate delivery versus expectant monitoring on maternal and neonatal outcomes in such women.We did an open-label, randomised controlled trial, in seven academic hospitals

2015 Lancet Controlled trial quality: predicted high

184. Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome

of CYP3A4 and P-gp, such as: 14.a rifampin 14.b carbamazepine 14.c phenytoin 14.d St. John's wort 15. Intend pregnancy or breastfeeding within the next year 16. Have a known allergy to apixaban, rivaroxaban, or edoxaban 17. Have experienced thrombosis while receiving warfarin at a target INR of 2-3 and have been assigned a higher target INR at the discretion of their clinician. 18. Patients with active pathological bleeding. 19. A history of arterial thromboembolism (e.g., stroke, myocardial infarction (...) Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Thrombosis Thromboembolism Antiphospholipid Syndrome Disease Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Autoimmune Diseases Immune System Diseases Warfarin Apixaban Anticoagulants Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular

2014 Clinical Trials

185. Prophylaxis of Venous Thromboembolism After Bariatric Surgery

: Rijnstate Hospital Information provided by (Responsible Party): Frits Berends, Rijnstate Hospital Study Details Study Description Go to Brief Summary: This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after bariatric surgery. Condition or disease Intervention/treatment Phase Morbid Obesity Thromboembolism Bypass Complications Drug (...) ) First Posted: November 20, 2014 Last Update Posted: November 20, 2014 Last Verified: November 2014 Keywords provided by Frits Berends, Rijnstate Hospital: Nadroparin Anti-Xa activity Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Obesity, Morbid Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Heparin, Low-Molecular-Weight Dalteparin Nadroparin

2014 Clinical Trials

186. Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging

, 2017 Sponsor: Massachusetts General Hospital Information provided by (Responsible Party): Robert Scott Harris, M.D., Massachusetts General Hospital Study Details Study Description Go to Brief Summary: This study with evaluate blood flow in the lungs of patients prior to and after surgery for treatment. Condition or disease Chronic Thromboembolic Pulmonary Hypertension Detailed Description: Specifically, we will evaluate the length-scale or size of blood flow alterations using filtering techniques (...) Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2014 Clinical Trials

187. Follow-up in Rivaroxaban Patients in Setting of Thromboembolism

anticoagulants (heparins and warfarin); 2. there will be less bleeding than when patients are on conventional anticoagulants; 3. there will be a lower long-term incidence of morbidity from chronic thromboembolic pulmonary hypertension and post-thrombotic limb syndrome. Condition or disease Intervention/treatment Venous Thromboembolism Other: Non-interventional study Detailed Description: United Kingdom-only prospective, non-interventional, investigator-led, multi-centre, single cohort, registry (...) relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Rivaroxaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants

2014 Clinical Trials

188. Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

physician, ongoing drug or alcohol addiction (> 8 drinks/week) Pregnancy /breast feeding Severely impaired renal function, GFR < 30 ml/min Impaired liver function (ALT/AST transaminase count 3fold higher than normal values) or liver disease with reduced life expectancy <1 year Valvular AF (moderate- severe mitral insufficiency; relevant mitral steno-sis with a mean pressure gradient >5mmHg) Long standing persistent (>12 months) and permanent AF NSTEMI/STEMI/implantated drug eluting stent with indication (...) Hospital, Bonn ClinicalTrials.gov Identifier: Other Study ID Numbers: MED2-201301 2013-003492-35 ( EudraCT Number ) First Posted: February 20, 2014 Last Update Posted: September 3, 2018 Last Verified: August 2018 Additional relevant MeSH terms: Layout table for MeSH terms Atrial Fibrillation Thromboembolism Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Embolism and Thrombosis Vascular Diseases Dabigatran Antithrombins Serine Proteinase Inhibitors Protease Inhibitors

2014 Clinical Trials

189. Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

will receive the study drug and 287 will receive an inactive substance. Analysis will be performed to assess the safety and the superiority of the study drug. Condition or disease Intervention/treatment Phase Venous Thromboembolism Cancer Drug: Apixaban Drug: Placebo drug Phase 2 Detailed Description: Patients holding a malignancy have a 7 to 28-fold higher risk for venous thromboembolism (VTE) than non-cancer patients(1). Since most cancer patients are currently treated in the outpatient setting, an acute (...) Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Apixaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants

2014 Clinical Trials

190. MERIT-2: Macitentan in thE tReatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension (OL)

: NCT02060721 Recruitment Status : Active, not recruiting First Posted : February 12, 2014 Last Update Posted : December 20, 2018 Sponsor: Actelion Information provided by (Responsible Party): Actelion Study Details Study Description Go to Brief Summary: Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Condition or disease Intervention/treatment Phase Chronic Thromboembolic Pulmonary (...) of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception. Exclusion Criteria: Permanent discontinuation of DB study treatment due to an hepatic adverse event or liver aminotransferase abnormalities. Any known factor (e.g., drug or substance abuse) or disease (e.g., unstable psychiatric illness) that, in the opinion of the investigator, may interfere with treatment compliance

2014 Clinical Trials

191. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. (PubMed)

Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Recommendations for venous thromboembolism (VTE) prophylaxis in patients with inflammatory bowel disease (IBD) can be refined by incorporating patient-specific risk factors.To determine the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in children and adults with Crohn's disease and ulcerative colitis and evaluate whether this risk varies by age (...) and/or presence of other risk factors.We performed a cohort study using Danish administrative data. Incidence rates of DVT and PE were calculated among patients with IBD and an age- and gender-matched comparison population and compared using Cox proportional hazards regression. We performed additional analyses stratifying by age, gender and disease type and restricting outcomes to unprovoked events (occurring without known malignancy, surgery, fracture/trauma or pregnancy). We next performed a nested case

2011 Gut

192. Aortic Diseases

aortic event improve steadily, a speci?c section is dedicated for chronicAD andfollow-upof patients aftertheacutephaseof AAS. Special emphasis is put on genetic and congenital aortic diseases, becausepreventivemeasuresplayanimportantroleinavoidingsub- sequent complications. Aortic diseases of elderly patients often present as thromboembolic diseases or atherosclerotic stenosis. Thecalci?edaortacanbeamajorproblemforsurgicalorinterven- tionalmeasures.Thecalci?ed‘coralreef’aortahastobeconsidered (...) Aortic Diseases ESC GUIDELINES 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC) Authors/Task Force members: Raimund Erbel * (Chairperson) (Germany), Victor Aboyans * (Chairperson) (France), Catherine Boileau (France), Eduardo Bossone (Italy), Roberto Di Bartolomeo

2014 European Society of Cardiology

193. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. (PubMed)

years. Measures of calibration and discrimination undertaken in validation cohort.564 general practices in England and Wales contributing to the QResearch database.Patients aged 25-84 years, with no record of pregnancy in the preceding 12 months or any previous venous thromboembolism, and not prescribed oral anticoagulation at baseline: 2,314,701 in derivation cohort and 1,240,602 in validation cohort. Outcomes Incident cases of venous thromboembolism, either deep vein thrombosis or pulmonary (...) Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. To derive and validate a new clinical risk prediction algorithm (QThrombosis, www.qthrombosis.org) to estimate individual patients' risk of venous thromboembolism.Prospective open cohort study using routinely collected data from general practices. Cox proportional hazards models used in derivation cohort to derive risk equations evaluated at 1 and 5

Full Text available with Trip Pro

2011 BMJ

194. Maternal Comorbidities and Complications of Delivery in Pregnant Women With Congenital Heart Disease. (PubMed)

to 238.0), congestive heart failure (aOR: 49.1; 95% CI: 37.4 to 64.3), and coronary artery disease (aOR: 31.7; 95% CI: 21.4 to 47.0). Greater odds of adverse events were observed, including heart failure (aOR: 22.6; 95% CI: 20.5 to 37.3), arrhythmias (aOR: 12.4; 95% CI: 11.0 to 14.0), thromboembolic events (aOR: 2.4; 95% CI: 2.0 to 2.9), pre-eclampsia (aOR: 1.5; 95% CI: 1.3 to 1.7), and placenta previa (aOR: 1.5; 95% CI: 1.2 to 1.8). Cesarean section, induction, and operative vaginal delivery were more (...) Maternal Comorbidities and Complications of Delivery in Pregnant Women With Congenital Heart Disease. Pregnant women with congenital heart defects (CHDs) may be at increased risk for adverse events during delivery.This study sought to compare comorbidities and adverse cardiovascular, obstetric, and fetal events during delivery between pregnant women with and without CHDs in the United States.Comorbidities and adverse delivery events in women with and without CHDs were compared in 22,881,691

Full Text available with Trip Pro

2019 Journal of the American College of Cardiology

195. Management of Women with Obesity in Pregnancy

to women with a healthy pre-pregnancy weight, pregnant women with obesity are at increased risk of miscarriage, 6 gestational diabetes, 10 pre-eclampsia, 11 venous thromboembolism, 8,9 induced labour, 20 caesarean section, 17 anaesthetic complications 21,22 and wound infections, 10 and they are less likely to initiate or maintain breastfeeding. 18 Babies of obese mothers are at increased risk of stillbirth, 13 14 congenital anomalies, 7 prematurity, 23 macrosomia 10,15,20 and neonatal death. 14-16 (...) – 337.6) for antenatal venous thromboembolism (VTE) and 40.1 (95% CI 8.0–201.5) for postnatal VTE in women with a BMI =25 where there was evidence of immobilisation, compared with women with a BMI 40) (aOR 4.82, 95% CI 4.04–5.74). 15 Similar increases in risk have been reported for pregnancy induced hypertension and pre-eclampsia in an Australian cohort study, in which the incidence ranged from 2.4% in women with a BMI 19.8-26.0 to 14.5% (aOR 4.87, 95% CI 3.27– 7.24) in women with a BMI >40. 23

2010 Royal College of Obstetricians and Gynaecologists

196. Risk of thromboembolic disease in women taking oral contraceptives. A preliminary communication to the Medical Research Council by a Subcommittee. (PubMed)

Contraceptives, Oral adverse effects Coronary Disease chemically induced Female Humans Intracranial Embolism and Thrombosis chemically induced Middle Aged Phlebitis chemically induced Pregnancy Pulmonary Embolism chemically induced Retrospective Studies Thromboembolism chemically induced Thrombophlebitis chemically induced 1967 5 6 1967 5 6 0 1 1967 5 6 0 0 ppublish 6023133 PMC1841690 Br Med J. 1967 Mar 25;1(5542):726-9 6020089 Br Med J. 1965 Nov 13;2(5471):1164-6 5833621 (...) Risk of thromboembolic disease in women taking oral contraceptives. A preliminary communication to the Medical Research Council by a Subcommittee. 6023133 1967 06 23 2018 11 13 0007-1447 2 5548 1967 May 06 British medical journal Br Med J Risk of thromboembolic disease in women taking oral contraceptives. A preliminary communication to the Medical Research Council by a Subcommittee. 355-9 eng Journal Article England Br Med J 0372673 0007-1447 0 Contraceptives, Oral AIM IM Adolescent Adult

Full Text available with Trip Pro

1967 British medical journal

197. Oral contraceptives and thromboembolic disease. (PubMed)

Oral contraceptives and thromboembolic disease. 6023128 1967 06 23 2018 11 13 0007-1447 2 5548 1967 May 06 British medical journal Br Med J Oral contraceptives and thromboembolic disease. 327-8 eng Journal Article England Br Med J 0372673 0007-1447 0 Contraceptives, Oral AIM IM Adult Contraceptives, Oral adverse effects Female Humans Pregnancy Thromboembolism chemically induced 1967 5 6 1967 5 6 0 1 1967 5 6 0 0 ppublish 6023128 PMC1841739 Br Med J. 1966 May 28;1(5499):1327-8 5934376

Full Text available with Trip Pro

1967 British medical journal

198. Acute and recurrent thromboembolic disease: a new concept of etiology. (PubMed)

Acute and recurrent thromboembolic disease: a new concept of etiology. 5344031 1969 12 02 2018 11 13 0003-4932 170 4 1969 Oct Annals of surgery Ann. Surg. Acute and recurrent thromboembolic disease: a new concept of etiology. 547-58 Altemeier W A WA Hill E O EO Fullen W D WD eng Journal Article United States Ann Surg 0372354 0003-4932 9005-49-6 Heparin AIM IM Acute Disease Adult Aged Bacteroides Chronic Disease Female Fusobacterium Infections complications Heparin administration & dosage (...) therapeutic use Humans Infection microbiology L Forms pathogenicity Male Middle Aged Peptostreptococcus Pregnancy Pulmonary Embolism etiology Staphylococcal Infections complications Streptococcal Infections complications Thromboembolism etiology microbiology Thrombophlebitis etiology microbiology Varicose Veins complications 1969 10 1 1969 10 1 0 1 1969 10 1 0 0 ppublish 5344031 PMC1387770 Surgery. 1951 Aug;30(2):298-310 14855228 J Bacteriol. 1941 Mar;41(3):301-3 16560400 J Bacteriol. 1964 Dec;88:1805-7

Full Text available with Trip Pro

1969 Annals of Surgery

199. Oral contraception and thromboembolic disease. (PubMed)

Oral contraception and thromboembolic disease. 5652942 1968 07 29 2018 11 13 0008-4409 98 23 1968 Jun 08 Canadian Medical Association journal Can Med Assoc J Oral contraception and thromboembolic disease. 1117-8 eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 0 Contraceptives, Oral AIM IM Adult Contraceptives, Oral adverse effects Female Humans Pregnancy Pulmonary Embolism etiology mortality Thromboembolism etiology mortality 1968 6 8 1968 6 8 0 1 1968 6 8 0 0 ppublish 5652942

Full Text available with Trip Pro

1968 Canadian Medical Association Journal

200. Oral contraceptives and thromboembolic disease. (PubMed)

Oral contraceptives and thromboembolic disease. 5648983 1968 07 04 2008 11 20 0007-1447 2 5601 1968 May 11 British medical journal Br Med J Oral contraceptives and thromboembolic disease. 366-7 Crawford J S JS eng Journal Article England Br Med J 0372673 0007-1447 0 Contraceptives, Oral AIM IM Contraceptives, Oral adverse effects Female Humans Pregnancy Thromboembolism chemically induced 1968 5 11 1968 5 11 0 1 1968 5 11 0 0 ppublish 5648983 PMC1985616

Full Text available with Trip Pro

1968 British medical journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>